We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Growth Factor Relieves Symptoms of Parkinson's Disease

By Biotechdaily staff writers
Posted on 08 Apr 2003
In a phase 1 clinical trial, a growth factor administered by catheter to the brains of patients with advanced Parkinson's disease produced an improvement in their motor skills as well as the ability to store dopamine, which helps the brain control muscles. More...
The results were reported in the March 31, 2003, issue of Nature Medicine.

The growth factor used is a protein known as glial cell-line-derived neurotrophic factor, or GDNF. Every day for 18 months, pumps pushed up to 40 micrograms of the protein into the putamen of the brain. There, it was absorbed by cells near the tip of the catheter and, the researchers suspect, drawn deeper into the brain where the dopamine-producing cells reside. After one year, the patients exhibited no serious side effects. The treatment also lessened the tremors caused by L-dopa. Tests measuring motor skills showed a 39% improvement, while tests measuring daily living activities showed a 61% improvement.

"What we're seeing is that GDNF either upregulated dopamine metabolism, or it has inspired sprouting (of cells),” said co-author Clive Svendsen, of the University of Wisconsin-Madison (USA). "Either way, you've got more dopamine, which is good news.” The study was carried out at the Frenchay Hospital, Institute of Neurosciences, in Bristol (UK), coordinated by neurosurgeon Steven S. Gill and neurologist Peter Heywood.




Related Links:
Frenchay Hospital

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Immunofluorescence Analyzer
IFA System
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.